Co-Authors
This is a "connection" page, showing publications co-authored by RAVIN RATAN and SHREYASKUMAR PATEL.
Connection Strength
2.248
-
Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? Curr Treat Options Oncol. 2017 06; 18(6):34.
Score: 0.595
-
Chemotherapy for soft tissue sarcoma. Cancer. 2016 10; 122(19):2952-60.
Score: 0.560
-
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
Score: 0.192
-
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
Score: 0.061
-
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
Score: 0.060
-
Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
Score: 0.060
-
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
Score: 0.059
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
Score: 0.059
-
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
Score: 0.058
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.056
-
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
Score: 0.055
-
The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
Score: 0.054
-
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
Score: 0.054
-
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104.
Score: 0.054
-
Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist. 2021 03; 26(3):250-260.
Score: 0.047
-
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 2021 04 15; 127(8):1311-1317.
Score: 0.047
-
Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel). 2020 Oct 11; 12(10).
Score: 0.047
-
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).
Score: 0.046
-
PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.
Score: 0.046
-
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
Score: 0.037